Articles related to TARGETED THERAPIES

Significant progress has been made in the last 20 years in the identification of therapeutically relevant oncogenic drivers in NSCLC. These oncogenic drivers have been the focus of targeted medicines that have been created to offer enhanced tailored treatment for NSCLC. To improve the choice of patient-specific treatment, an oral presentation at the 2023 ONA Summit Live Virtual Meeting compared guideline-directed targeted therapies based on patient and tumor characteristics. It also described collaborative strategies for managing therapy-related adverse events for this patient population. Key molecular characteristics in advanced NSCLC were also discussed, along with their relationships to current and emerging targeted therapies.

Following participation in this educational activity, hematologists/oncologists, nurses, pharmacists, and other members of the interprofessional team involved in the management of DLBCL patients should be better able to:

The article discusses the expanding landscape of targeted therapies for patients with advanced metastatic non-small-cell lung cancer (NSCLC), with nine targetable oncogenes and seven approvals within the last five years. With these emerging therapeutic options, the article emphasizes the importance of understanding the existing data on immune checkpoint inhibitors (ICIs) for each oncogene-driven lung cancer to guide the selection and sequencing of therapeutic options. The article reviews the clinical data on ICIs for each of the driver oncogene-defined lung cancer subtypes, including efficacy, toxicities, and potential strategies to enhance ICI efficacy in oncogene-driven NSCLC.

In his discussion of the subject, Adam M. Brufsky, MD, PhD, FACP, of the University of Pittsburgh School of Medicine notes that about 50% of breast cancers categorized as HER2-negative exhibit low HER2 expression, and preliminary data suggest that new antibody-drug conjugates may be effective in treating tumors with low HER2 expression; clinical trials are currently underway. Trastuzumab should not be added to treatment plans for women with low HER2 expression, according to Dr. Brufsky, because it does not assist those with IHC 3+ or ISH-amplified breast cancer or those without those conditions. Finally, compared to triple-negative tumors, hormone receptor-positive (HR+)/HER2-negative cancers seem to have low HER2 expression more commonly.

Taking place February 3 – 5, 2023 at the JW Marriott Scottsdale Camelback Inn Resort & Spa in Paradise Valley, Arizona, live and virtual attendees will learn how to distinguish between immunotherapy combinations in metastatic RCC, identify actionable target therapy in the treatment of metastatic lung cancer, identify targeted therapies for CNS metastases, review management of resectable melanoma – neoadjuvant versus adjuvant immune checkpoint blockade, and assess the approved and developing categories of prostate cancer patients eligible for PSMA-targeted therapy.

JAK inhibitors have been the go-to treatment for people with myelofibrosis (MF). Despite successfully reducing MPN-related symptoms, currently approved JAK inhibitors are not known to significantly change the course of MF disease. Similar to essential thrombocythemia (ET) and polycythemia vera (PV), therapy in these conditions focus primarily on lowering the risk of cardiovascular and thromboembolic consequences; in individuals with reduced thrombosis risks, careful waiting is frequently employed. The creation of rationally tailored medicines, however, with the aim of not only managing illness problems but also potentially altering disease course, has resulted from a greater understanding of MPN biology.